|
1
|
Burnett AK, Kell WJ, Goldstone AH, et al:
The addition of gemtuzumab ozogamicin to induction chemotherapy for
AML improves disease free survival without extra toxicity:
Preliminary analysis of 1115 patients in the MRC AML15 Trial. ASH
Annual Meeting Abstracts. 108:132006.
|
|
2
|
Bassan R, Spinelli O, Oldani E, et al:
Improved risk classification for risk-specific therapy based on the
molecular study of minimal residual disease (MRD) in adult acute
lymphoblastic leukemia (ALL). Blood. 113:4153–4162. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oran B and de Lima M: Prevention and
treatment of acute myeloid leukemia relapse after allogeneic stem
cell transplantation. Curr Opin Hematol. 18:388–394. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brentjens RJ, Rivière I, Park J H, et al:
Safety and persistence of adoptively transferred autologous CD19-
targeted T cells in patients with relapsed or chemotherapy
refractory B-cell leukemias. Blood. 118:4817–4828. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ruggeri L, Mancusi A, Burchielli E, et al:
Natural killer cell alloreactivity and haplo-identical
hematopoietic transplantation. Cytotherapy. 8:554–558. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Colvin GA, Berz D, Ramanathan M, et al:
Nonengraftment haploidentical cellular immunotherapy for refractory
malignancies: tumor responses without chimerism. Biol Blood Marrow
Transplant. 15:421–431. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Warlick ED, DeFor T, Blazar BR, et al:
Successful remission rates and survival after lymphodepleting
chemotherapy and donor lymphocyte infusion for relapsed hematologic
malignancies postallogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant. 18:480–486. 2012. View Article : Google Scholar
|
|
8
|
Barrett AJ and Le Blanc K: Immunotherapy
prospects for acute myeloid leukaemia. Clin Exp Immunol.
161:223–232. 2010.PubMed/NCBI
|
|
9
|
Schmidt-Wolf IG, Negrin RS, Kiem HP, et
al: Use of a SCID mouse/human lymphoma model to evaluate
cytokine-induced killer cells with potent antitumor cell activity.
J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vivier E, Ugolini S, Blaise D, et al:
Targeting natural killer cells and natural killer T cells in
cancer. Nat Rev Immunol. 12:239–252. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gütgemann S, Frank S, Strehl J and
Schmidt-Wolf IG: Cytokine-induced killer cells are type II natural
killer T cells. Ger Med Sci. 5:Doc072007.PubMed/NCBI
|
|
12
|
Sangiolo D, Martinuzzi E, Todorovic M, et
al: Alloreactivity and anti-tumor activity segregate within two
distinct subsets of cytokine-induced killer (CIK) cells:
implications for their infusion across major HLA barriers. Int
Immunol. 20:841–848. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim HM, Kang JS, Lim J, et al: Antitumor
activity of cytokine-induced killer cells in nude mouse xenograft
model. Arch Pharm Res. 32:781–787. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Linn YC, Lau SK, Liu BH, et al:
Characterization of the recognition and functional heterogeneity
exhibited by cytokine-induced killer cell subsets against acute
myeloid leukaemia target cell. Immunology. 126:423–435. 2009.
View Article : Google Scholar :
|
|
15
|
Franceschetti M, Pievani A, Borleri G, et
al: Cytokine-induced killer cells are terminally differentiated
activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol.
37:616–628. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Verneris MR: Role of NKG2D signaling in
the cytotoxicity of activated and expanded CD8+ T cells. Blood.
103:3065–3072. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Linn YC, Wang SM and Hui KM: Comparative
gene expression profiling of cytokine-induced killer cells in
response to acute myloid leukemic and acute lymphoblastic leukemic
stimulators using oligonucleotide arrays. Exp Hematol. 33:671–681.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pievani A, Borleri G, Pende D, et al:
Dual-functional capability of CD3+ CD56+ CIK cells, a T-cell subset
that acquires NK function and retains TCR-mediated specific
cytotoxicity. Blood. 118:3301–3310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu J, Zhang W, Jiang H, et al: CD4+ T
cells in CIKs (CD4+ CIKs) reversed resistance to Fas-mediated
apoptosis through CD40/CD40L ligation rather than IFN-gamma
stimulation. Cancer Biother Radiopharm. 23:342–354. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hoyle C, Bangs CD, Chang P, et al:
Expansion of Philadelphia chromosome-negative CD3(+)CD56(+)
cytotoxic cells from chronic myeloid leukemia patients: in vitro
and in vivo efficacy in severe combined immunodeficiency disease
mice. Blood. 92:3318–3327. 1998.PubMed/NCBI
|
|
21
|
Linn YC, Lau LC and Hui KM: Generation of
cytokine-induced killer cells from leukemic samples with in vitro
cytotoxicity against autologous and allogeneic leukaemic blasts. Br
J Haematol. 116:78–86. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kornacker M, Moldenhauer G, Herbst M, et
al: Cytokine-induced killer cells against autologous CLL: direct
cytotoxic effects and induction of immune accessory molecules by
interferon-gamma. Int J Cancer. 119:1377–1382. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Scheffold C, Brandt K, Johnston V, et al:
Potential of autologous immunologic effector cells for bone marrow
purging in patients with chronic myeloid leukemia. Bone Marrow
Transplant. 15:33–39. 1995.PubMed/NCBI
|
|
24
|
Nishimura R, Baker J, Beilhack A, et al:
In vivo trafficking and survival of cytokine-induced killer cells
resulting in minimal GVHD with retention of antitumor activity.
Blood. 112:2563–2574. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sangiolo D, Mesiano G, Carnevale-Schianca
F, et al: Cytokine induced killer cells as adoptive immunotherapy
strategy to augment graft versus tumor after hematopoietic cell
transplantation. Expert Opin Biol Ther. 9:831–840. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mase S, Fujiki T, Kuroda R, Araki R, et
al: Allogeneic cytokine-induced killer cells eliminate host
dendritic cells due to the enhanced killing activity by IFN-gamma,
leading to less graft-versus-host disease. Blood. 122:44952013.
|
|
27
|
Yun YS, Hargrove ME and Ting CC: In vivo
antitumor activity of anti-CD3-induced activated killer cells.
Cancer Res. 49:4770–4774. 1989.PubMed/NCBI
|
|
28
|
Rosenberg SA, Spiess P and Lafreniere R: A
new approach to the adoptive immunotherapy of cancer with
tumor-infiltrating lymphocytes. Science. 233:1318–1321. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Grabert RC, Cousens LP, Smith JA, Olson S,
Gall J, Young WB, et al: Human T cells armed with Her2/neu
bispecific antibodies divide, are cytotoxic, and secrete cytokines
with repeated stimulation. Clin Cancer Res. 12:569–576. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schmidt-Wolf GD, Negrin RS and
Schmidt-Wolf IG: Activated T cells and cytokine-induced CD3+CD56+
killer cells. Ann Hematol. 74:51–56. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Raulet DH, Gasser S, Gowen BG, et al:
Regulation of ligands for the NKG2D activating receptor. Annu Rev
Immunol. 31:413–441. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vesely MD and Schreiber RD: Cancer
immunoediting: antigens, mechanisms, and implications to cancer
immunotherapy. Ann NY Acad Sci. 1284:1–5. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang B, Sikorski R, Sampath P and Thorne
SH: Modulation of NKG2D-ligand cell surface expression enhances
immune cell therapy of cancer. J Immunother. 34:289–296. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang QJ, Wang H, Pan K, et al: Comparative
study on anti-tumor immune response of autologous cytokine-induced
killer (CIK) cells, dendritic cells-CIK (DC-CIK), and
semi-allogeneic DC-CIK. Chin J Cancer. 29:641–648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ge W, Li CH, Zhang W, et al: Coculture of
dendritic cell with cytokine-induced killer results in a
significant increase in cytotoxic activity of CIK to tumor cells in
vitro and in vivo. Zhonghua Xue Ye Xue Za Zhi. 25:277–280. 2004.(In
Chinese). PubMed/NCBI
|
|
36
|
Rettinger E, Kuçi S, Naumann I, et al: The
cytotoxic potential of interleukin-15-stimulated cytokine-induced
killer cells against leukemia cells. Cytotherapy. 14:91–103. 2012.
View Article : Google Scholar
|
|
37
|
Zhao N, Zhao MF, Rajbhandary S, et al:
Effects of humanized interleukin 21 on anti-leukemic activity of
cytokine induced killer cells and the mechanism. Zhonghua Xue Ye
Xue Za Zhi. 33:823–828. 2012.(In Chinese).
|
|
38
|
Durrieu L, Gregoire-Gauthier J, Dieng MM,
et al: Human interferon-alpha increases the cytotoxic effect of
CD56(+) cord blood-derived cytokine-induced killer cells on human
B-acute lymphoblastic leukemia cell lines. Cytotherapy.
14:1245–1257. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xia W, Yu X, Wang P, et al: The
cytotoxicity of IL-24 gene-modified CIK cells to HL-60 cells. Chin
J Immunol. 25:1080–1084. 2009.
|
|
40
|
Marin V, Kakuda H, Dander E, et al:
Enhancement of the anti-leukemic activity of cytokine induced
killer cells with an anti-CD19 chimeric receptor delivering a
4-1BB-zeta activating signal. Exp Hematol. 35:1388–1397. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Marin V, Pizzitola I, Agostoni V, et al:
Cytokine-induced killer cells for cell therapy of acute myeloid
leukemia: improvement of their immune activity by expression of
CD33-specific chimeric receptors. Haematologica. 95:2144–2152.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tettamanti S, Marin V, Pizzitola I, et al:
Targeting of acute myeloid leukaemia by cytokine. Induced killer
cells redirected with a novel CD123-specific chimeric antigen
receptor. Bri J Haematol. 161:389–401. 2013. View Article : Google Scholar
|
|
43
|
Hu L, Cao D, Li Y, et al: Resveratrol
sensitized leukemia stem cell-like KG-1a cells to cytokine-induced
killer cells-mediated cytolysis through NKG2D ligands and TRAIL
receptors. Cancer Biol Ther. 13:516–526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang JH, Liu LQ, He YL, et al: Cytotoxic
effect of trans-cinnamaldehyde on human leukemia K562 cells. Acta
Pharmacol Sin. 31:861–866. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kaneko T, Fusauch Y, Kakui Y, et al:
Cytotoxicity of cytokine-induced killer cells coated with
bispecific antibody against acute myeloid leukemia cells. Leuk
Lymphoma. 14:219–229. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bonanno G, Iudicone P, Mariotti A, et al:
Thymoglobulin, interferon-γ and interleukin-2 efficiently expand
cytokine-induced killer (CIK) cells in clinical-grade cultures. J
Transl Med. 8:1292010. View Article : Google Scholar
|
|
47
|
Zheng Z, Yuna Z, Huimin Z, Liu Q, et al:
Clinical study of DC-CIK (dendritic cells and cytokine-induced
killer cells) eliminate minimal residual leukemia. Blood.
122:14502013.
|
|
48
|
Thanendrarajan S, Nowak M, Abken H and
Schmidt-Wolf IG: Combining cytokine-induced killer cells with
vaccination in cancer immunotherapy: More than one plus one? Leuk
Res. 35:1136–1142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yang Z, Zhang Q, Xu K, et al: Combined
therapy with cytokine-induced killer cells and oncolytic adenovirus
expressing IL-12 induce enhanced antitumor activity in liver tumor
model. PLoS One. 7:e448022012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Niam M, Linn YC, Fook Chong S, et al:
Clinical scale expansion of cytokine-induced killer cells is
feasible from healthy donors and patients with acute and chronic
myeloid leukemia at various stages of therapy. Exp Hematol.
39:897–903. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Introna M, Borleri G, Conti E, et al:
Repeated infusions of donor-derived cytokine-induced killer cells
in patients relapsing after allogeneic stem cell transplantation: a
phase I study. Haematologica. 92:952–959. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Introna M, Pievani A, Borleri G, et al:
Feasibility and safety of adoptive immunotherapy with CIK cells
after cord blood transplantation. Biol Blood Marrow Transplant.
16:1603–1607. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Linn YC, Niam M, Chu S, et al: The
anti-tumour activity of allogeneic cytokine-induced killer cells in
patients who relapse after allogeneic transplant for haematological
malignancies. Bone Marrow Transplant. 47:957–966. 2012. View Article : Google Scholar
|
|
54
|
Linn YC, Yong HX, Niam M, et al: A phase
I/II clinical trial of autologous cytokine-induced killer cells as
adjuvant immunotherapy for acute and chronic myeloid leukemia in
clinical remission. Cytotherapy. 14:851–859. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhong R, Teng J, Han B and Zhong H:
Dendritic cells combining with cytokine-induced killer cells
synergize chemotherapy in patients with late-stage non-small cell
lung cancer. Cancer Immunol Immunother. 60:1497–1502. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jiang H, Liu KY, Tong CR, et al: The
efficacy of chemotherapy in combination with auto-cytokine-induced
killer cells in acute leukemia. Zhonghua Nei Ke Za Zhi. 44:198–201.
2005.(In Chinese). PubMed/NCBI
|
|
57
|
Benjamin J, Laport GG, Tate K, Galvez L,
et al: Early infusion of donor-derived CIK cells as consolidative
immunotherapy following non-myeloablative allogeneic
transplantation: safety and feasibility. Blood. 122:8992013.
|
|
58
|
Zhou X, Zhu J, Sun H, et al: Family
haploidentical donor-derived cytokine-induced killer cell
biotherapy combined with bortezomib in two patients with relapsed
multiple myeloma in a non-allogeneic transplant setting. Leukemia
Lymphoma. 54:209–211. 2013. View Article : Google Scholar
|
|
59
|
Hontscha C, Borck Y, Zhou H, et al:
Clinical trials on CIK cells: first report of the international
registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 137:305–331.
2011. View Article : Google Scholar
|
